Log In- MESH
- Blue Cross Blue Shield Insurance Plans
- Clinical Trials as Topic
- Diagnostic Techniques and Procedures
- Diagnostic Test Approval
- Humans
- Individualized Medicine
- Melanoma
- Molecular Diagnostic Techniques
- Molecular Targeted Therapy
- Mutation
- Patient Selection
- Pharmacogenetics
- Proto-Oncogene Proteins B-raf
- Technology Assessment, Biomedical
- United States
- United States Food and Drug Administration
Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
Source
Technology Evaluation Center Assessment Program. Executive summary 26:7 2011 Nov pg 1-5MeSH
Blue Cross Blue Shield Insurance PlansClinical Trials as Topic
Diagnostic Techniques and Procedures
Diagnostic Test Approval
Humans
Individualized Medicine
Melanoma
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Mutation
Patient Selection
Pharmacogenetics
Proto-Oncogene Proteins B-raf
Technology Assessment, Biomedical
United States
United States Food and Drug Administration
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22724160